432,996 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by Clear Street Group Inc.

Clear Street Group Inc. purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 432,996 shares of the biotechnology company’s stock, valued at approximately $9,318,000. Clear Street Group Inc. owned about 0.41% of Sarepta Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $25,000. iSAM Funds UK Ltd purchased a new position in shares of Sarepta Therapeutics during the third quarter worth about $25,000. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after buying an additional 1,256 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $15.31 on Friday. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. The company has a market cap of $1.62 billion, a P/E ratio of -15.95, a PEG ratio of 0.16 and a beta of 0.21. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $38.09. The company has a 50-day moving average price of $19.23 and a 200 day moving average price of $19.75.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The firm had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. During the same quarter last year, the firm earned ($3.42) earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. Research analysts predict that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on SRPT. Oppenheimer reissued an “outperform” rating and set a $37.00 price target on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Deutsche Bank Aktiengesellschaft raised their price target on Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a report on Thursday, March 26th. Royal Bank Of Canada raised their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Mizuho raised their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Eight research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $24.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.